Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides glucose for cellular energy metabolism; sodium chloride corrects electrolyte imbalances; potassium chloride maintains intracellular potassium levels and repolarizes cell membranes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Intravenous fluid replacement in patients with hypokalemia and volume depletion,Maintenance of hydration and electrolyte balance when oral intake is insufficient
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; typical adult maintenance dose is 1000-2000 m L per day at a rate of 50-100 m L/hour, providing 40 m Eq of potassium chloride per liter.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: <1 hour (rapidly metabolized). Sodium/chloride/potassium: not applicable as electrolytes are regulated by homeostatic mechanisms, not eliminated via half-life.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose undergoes glycolysis and oxidative metabolism; potassium is primarily excreted by the kidneys; sodium is regulated by renal mechanisms.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is metabolized to CO2 and water, with <5% excreted unchanged renally. Sodium and chloride are primarily excreted renally (≥90%), with minimal fecal or biliary elimination. Potassium is >90% excreted renally, with minor fecal loss (≤8%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible. Sodium, chloride: negligible. Potassium: minimal (unbound in blood).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: Vd 0.2-0.3 L/kg (total body water). Sodium: Vd ~0.6 L/kg (extracellular water). Chloride: Vd ~0.3 L/kg. Potassium: Vd ~0.4 L/kg (mostly intracellular; distribution after infusion is delayed).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (complete bioavailability). Oral: not applicable; this product is for IV use only.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce daily potassium to 0.5-1 m Eq/kg; monitor potassium and adjust rate. GFR <10 m L/min: avoid use or use with extreme caution; reduce potassium intake to <0.5 m Eq/kg/day and monitor ECG.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce potassium dose by 50% and monitor serum potassium. Child-Pugh C: avoid use; alternative potassium replacement strategies recommended.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion; dose based on fluid and electrolyte needs: dextrose 5% with 0.33% sodium chloride and 40 m Eq/L potassium chloride. Typical starting rate: 100 m L/kg/day for first 10 kg, then 50 m L/kg/day for next 10 kg, then 20 m L/kg/day for additional weight; adjust according to serum potassium and glucose levels. Do not exceed 0.5-1 m Eq/kg/hour of potassium.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Intravenous infusion; start at lower end of adult dosing (e.g., 50-100 m L/hour) and titrate based on renal function, potassium levels, and fluid status. Monitor for volume overload and hyperkalemia due to age-related decrease in renal function and total body potassium. Consider using potassium chloride 20 m Eq/L if hypokalemia is mild.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Concentrated potassium solutions should be diluted and administered slowly to avoid fatal hyperkalemia. Do not administer unless solution is clear and container undamaged.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum potassium, glucose, and electrolytes during therapy,Risk of fluid overload in patients with renal impairment or heart failure,May cause hyperkalemia if given too rapidly or with potassium-sparing diuretics,Use with caution in patients with diabetes mellitus or glucose intolerance
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Severe renal impairment (anuria/oliguria),Hypernatremia,Fluid overload (e.g., pulmonary edema, heart failure),Hypersensitivity to any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No direct food interactions; however, patients on potassium-sparing diuretics or with high potassium intake (e.g., salt substitutes, potassium-rich foods) should be monitored for hyperkalemia.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose, sodium chloride, and potassium chloride are essential nutrients; at physiological doses, they are not associated with teratogenic effects. High-dose potassium chloride may cause maternal hyperkalemia, which can lead to fetal arrhythmia. Trimester-specific risks: 1st trimester: no known structural teratogenicity. 2nd/3rd trimester: electrolyte imbalances may affect fetal homeostasis; hyperkalemia may induce fetal bradycardia or arrhythmia.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose, sodium, potassium, and chloride are normal constituents of breast milk. Exogenous administration at therapeutic doses does not significantly alter milk composition. M/P ratio: not applicable as these are endogenous substances. Generally considered compatible with breastfeeding when used as per standard clinical indications.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy increases plasma volume and glomerular filtration rate, potentially increasing clearance of potassium and dextrose. No standardized dose adjustment; infusion rate should be guided by maternal electrolyte and glucose levels, and clinical status. Avoid potassium infusion rates exceeding 10 m Eq/hour and total daily potassium dose of 40-60 m Eq unless severe hypokalemia. Dextrose infusion may require insulin in gestational diabetes.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This solution provides 5% dextrose (caloric source), 0.33% sodium chloride (hypotonic saline), and 40 m Eq/L potassium chloride. Use with caution in patients with renal impairment due to potassium retention risk. Avoid in patients with hyperkalemia. Monitor serum potassium and glucose levels. Not for use as a maintenance solution in pediatric patients due to hypotonicity risk.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This intravenous fluid contains sugar (dextrose), salt (sodium chloride), and potassium.,Tell your doctor if you have kidney problems, high potassium levels, or diabetes.,You may experience pain or swelling at the IV site. Report any discomfort.,Do not adjust the flow rate yourself. The infusion rate is controlled by the healthcare team.,This medication is given under medical supervision only.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides glucose for cellular energy metabolism; sodium chloride corrects electrolyte imbalances; potassium chloride maintains intracellular potassium levels and repolarizes cell membranes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER is: Intravenous infusion; typical adult maintenance dose is 1000-2000 m L per day at a rate of 50-100 m L/hour, providing 40 m Eq of potassium chloride per liter.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are essential nutrients; at physiological doses, they are not associated with teratogenic effects. High-dose potassium chloride ma. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.